Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.

Autor:	Kaku Y; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Kuwata T; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: tkuwata@kumamoto-u.ac.jp., Zahid HM; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Hashiguchi T; Labolatory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan., Noda T; Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan., Kuramoto N; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Biswas S; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Matsumoto K; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Shimizu M; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Kawanami Y; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Shimura K; Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan., Onishi C; Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan., Muramoto Y; Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan., Suzuki T; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan., Sasaki J; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan., Nagasaki Y; Division of Infectious Diseases, Clinical Research Institute, National Hospitalization Organization, Kyushu Medical Center, Fukuoka, Japan., Minami R; Internal Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan., Motozono C; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Toyoda M; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Takahashi H; Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan., Kishi H; Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan., Fujii K; Department of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan., Tatsuke T; Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan., Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan., Maeda Y; Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan., Ueno T; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan., Koyanagi Y; Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan., Iwagoe H; Department of Infectious Disease, Kumamoto City Hospital, Kumamoto 862-8505, Japan., Matsushita S; Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: shuzo@kumamoto-u.ac.jp.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2021 Jul 13; Vol. 36 (2), pp. 109385. Date of Electronic Publication: 2021 Jun 25.
DOI:	10.1016/j.celrep.2021.109385
Abstrakt:	Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG + ) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2. Competing Interests: Declaration of interests Y. Kaku, T.K., and S.M. are listed as inventors on a patent application related to this work. The remaining authors declare no competing interests. (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu